Literature DB >> 6610522

Fluoxetine kinetics and protein binding in normal and impaired renal function.

G R Aronoff, R F Bergstrom, S T Pottratz, R S Sloan, R L Wolen, L Lemberger.   

Abstract

The effect of decreased renal function on the disposition and elimination of the nontricyclic antidepressant fluoxetine was examined in 25 adult male subjects after a single 40-mg oral dose. Blood samples for the measurement of fluoxetine and its active metabolite norfluoxetine were drawn 13 times in the first 48 hr after dosing and thrice weekly thereafter for 4 wk. All urine was collected in daily aliquots for 4 wk and was assayed for fluoxetine and norfluoxetine concentrations. The extent of fluoxetine binding to plasma protein was determined by equilibrium dialysis. Kinetic analyses were by noncompartmental methods. The drug and its metabolite were distributed over a large apparent volume and both were eliminated slowly. No correlations between the degree of renal dysfunction and the rate of elimination, volume of distribution, or protein binding were found. Plasma concentrations of fluoxetine and norfluoxetine were not significantly changed by hemodialysis.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6610522     DOI: 10.1038/clpt.1984.152

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  26 in total

Review 1.  Metabolism and pharmacokinetics of selective serotonin reuptake inhibitors.

Authors:  C L DeVane
Journal:  Cell Mol Neurobiol       Date:  1999-08       Impact factor: 5.046

2.  Fluoxetine disposition in patients with chronic hepatitis C treated with interferon-α.

Authors:  Mario Furlanut; Giorgio Soardo; Debora Donnini; Leonardo Sechi; Loretta Franceschi
Journal:  Clin Pharmacokinet       Date:  2010-11       Impact factor: 6.447

Review 3.  Disease-induced variations in plasma protein levels. Implications for drug dosage regimens (Part II).

Authors:  R Zini; P Riant; J Barré; J P Tillement
Journal:  Clin Pharmacokinet       Date:  1990-09       Impact factor: 6.447

4.  Fluoxetine and norfluoxetine are potent inhibitors of P450IID6--the source of the sparteine/debrisoquine oxidation polymorphism.

Authors:  K Brøsen; E Skjelbo
Journal:  Br J Clin Pharmacol       Date:  1991-07       Impact factor: 4.335

5.  Effects of drugs on 2',3'-dideoxy-2',3'-didehydrothymidine phosphorylation in vitro.

Authors:  P G Hoggard; S Kewn; M G Barry; S H Khoo; D J Back
Journal:  Antimicrob Agents Chemother       Date:  1997-06       Impact factor: 5.191

6.  Population PK modelling and simulation based on fluoxetine and norfluoxetine concentrations in milk: a milk concentration-based prediction model.

Authors:  Reo Tanoshima; Facundo Garcia Bournissen; Yusuke Tanigawara; Judith H Kristensen; Anna Taddio; Kenneth F Ilett; Evan J Begg; Izhar Wallach; Shinya Ito
Journal:  Br J Clin Pharmacol       Date:  2014-10       Impact factor: 4.335

Review 7.  The Role of Metabolites of Antidepressants in the Treatment of Depression.

Authors:  M V Rudorfer; W Z Potter
Journal:  CNS Drugs       Date:  1997-04       Impact factor: 5.749

Review 8.  Treatment of anxiety and depression in transplant patients: pharmacokinetic considerations.

Authors:  Catherine C Crone; Geoffrey M Gabriel
Journal:  Clin Pharmacokinet       Date:  2004       Impact factor: 6.447

Review 9.  Clinical pharmacokinetics of fluoxetine.

Authors:  A C Altamura; A R Moro; M Percudani
Journal:  Clin Pharmacokinet       Date:  1994-03       Impact factor: 6.447

10.  Time course of the effects of the serotonin-selective reuptake inhibitor sertraline on central and peripheral serotonin neurochemistry in the rhesus monkey.

Authors:  George M Anderson; Christina S Barr; Stephen Lindell; Amy C Durham; Ilya Shifrovich; J Dee Higley
Journal:  Psychopharmacology (Berl)       Date:  2004-09-25       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.